Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Eagles quarterback Jalen Hurts standing in confetti after winning the Super Bowl is magnificent. Jalen silenced the doubters on Sunday with a fantastic performance as the Eagles routed the Chiefs.

The Philadelphia Eagles demolished the Kansas City Chiefs in Super Bowl 59 40-22 – a score actually closer than the blowout it was for three quarters. The Eagles' victory at the Caesars ...

The Super Bowl is not just about football. It's perhaps the secret as to why the NFL's biggest game today enjoys unquestioned status as the most-watched event in the United States each year.

The Philadelphia Eagles demolished the two-time defending champion Kansas City Chiefs to win Super Bowl LIX 40-22 in New Orleans. The performance saw the Eagles avenge their Super Bowl LVII defeat ...

The Kansas City Chiefs could not complete the Super Bowl three-peat. Kansas City failed to match the Philadelphia Eagles' intensity on both sides of the ball, losing 40-22 with the score at 40-6 ...

As the Kansas City Chiefs and the Philadelphia Eagles engage in a rematch at Super Bowl LIX at Caesars Superdome in New Orleans, brands are pulling out all the stops with star-studded, nostalgia ...

Here's why they think Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years ...